ACE-031 from Super Human Peptides UK is an advanced, recombinant fusion protein. It is specifically engineered by fusing the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc portion of a human immunoglobulin G1 (IgG1) antibody. In laboratory research, ACE-031 represents the most direct, aggressive model for investigating myostatin blockade.
Unlike Follistatin, which is a naturally occurring binding protein, researchers utilize ACE-031 as a "soluble decoy receptor." It circulates in the bloodstream and mimics the body’s actual ActRIIB muscle receptors. By acting as a decoy, it binds to and traps myostatin (GDF-8) and other muscle-inhibiting ligands (like activin A and GDF-11) before they can reach the actual muscle cells.
Produced under GMP-compliant conditions and verified for 99% purity or higher, ACE-031 is an unparalleled tool for researching severe muscular dystrophy, extreme cellular hypertrophy, and simultaneous bone density increases.
- —Decoy Receptor Mechanism: A synthesized, circulating ActRIIB receptor that traps catabolic ligands in the bloodstream.
- —Broad-Spectrum Blockade: Neutralizes not only myostatin but also activin and GDF-11 for maximum hypertrophic signaling.
- —Musculoskeletal Dual-Action: Studied for simultaneous, profound increases in both skeletal muscle mass and bone mineral density.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Documentation: Full Certificate of Analysis (COA) included with every batch.
- —Decoy Receptor Kinetics: Studying the binding affinity of the ActRIIB-Fc fusion protein to circulating TGF-beta ligands compared to endogenous cell-surface receptors.
- —Muscular Dystrophy Rescue: Preclinical models investigating the preservation of respiratory and skeletal muscle function in highly progressive wasting diseases.
- —Bone Mineral Density (BMD): Researching the peptide's unique secondary effect of down-regulating osteoclast activity, thereby increasing bone mass alongside muscle tissue.
- —Age-Related Sarcopenia: Evaluating the reversal of frailty and the rapid restoration of lean cross-sectional muscle area in aged subjects.
- —Ligand Specificity: Investigating the physiological differences between isolated myostatin inhibition versus broad-spectrum ActRIIB ligand blockade.
ACE-031 was originally developed by Acceleron Pharma specifically to combat progressive neuromuscular diseases like Duchenne Muscular Dystrophy (DMD). While myostatin was the primary target, researchers discovered that myostatin is just one of several ligands that signal through the ActRIIB receptor to halt muscle growth. Laboratory studies utilizing the ActRIIB-Fc model have demonstrated unprecedented tissue growth.
Because ACE-031 traps multiple catabolic ligands simultaneously, animal models treated with the decoy receptor exhibit a far greater increase in muscle mass than those treated with agents that only block myostatin. In foundational preclinical studies, subjects achieved massive, rapid increases in total lean body mass, enhanced muscle force generation, and significantly elevated bone mineral density in a matter of weeks. It remains one of the most structurally sophisticated and potent agents in modern musculoskeletal research.
- 1.Cadena, S.M. et al., "Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of interleukin-6," Journal of Applied Physiology, 2010.
- 2.Attie, H.L. et al., "A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers," Muscle & Nerve, 2013.
- 3.Campbell, C. et al., "Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial," Muscle & Nerve, 2017.
- 4.Pearsall, R.S. et al., "A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity," Proceedings of the National Academy of Sciences, 2008. (Contextual mechanisms of ActRII fusion proteins).
